| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 03/18/2004 | US20040053853 Topiramate salts and compositions comprising and methods of making and using the same |
| 03/18/2004 | US20040053829 Polypeptide having preferably antitumoral and/or immunomodulating cytokine properties, which can be activated by processing in vivo comprising a central region with specific biological activity |
| 03/18/2004 | US20040053823 Polypeptides with amino acid sequences or peptidomimetics |
| 03/18/2004 | US20040053818 Solution for removing cataracts via liquefracture |
| 03/18/2004 | US20040053817 Proinsulin C-peptide is present in an absorbable matrix of polyglycolide-lactide copolymers; antidiabetic agents |
| 03/18/2004 | US20040053381 Polyhydroxyalkanoates for in vivo applications |
| 03/18/2004 | US20040053376 Procedure for the preparation of pure phosphatides and their use in the cosmetic, pharmaceutical and alimentary fields |
| 03/18/2004 | US20040053348 Nucleic acids and corresponding proteins entitled 282P1G3 useful in treatment and detection of cancer |
| 03/18/2004 | US20040052873 Bioavailability / bioefficacy enhancing activity of cuminum cyminum and extracts and fractions thereof |
| 03/18/2004 | US20040052857 Vesicle encapsulating an aqueous system of a polymer and can exist as more than one phase depending on temperature and composition |
| 03/18/2004 | US20040052855 Pouring a dissolved biodegradable polymer and a drug in a low water soluble solvents, a surfactant and homogenizing, filtering, washing and freeze drying |
| 03/18/2004 | US20040052849 Intercalate of a layered double hydroxide and a drug with an anionic group |
| 03/18/2004 | US20040052846 Delayed release pharmaceutical formulations |
| 03/18/2004 | US20040052845 Hydrogel-driven drug dosage form |
| 03/18/2004 | US20040052841 Pharmaceutical preparation with retarding active ingredient release, method for its production and its use |
| 03/18/2004 | US20040052840 Preparations for oligonucleotide transfer |
| 03/18/2004 | US20040052839 Mixing non-gelatin hydrocolloid, water, and a plasticizer into a homogeneous composition of >/= 40% water, extracting water to 25% and forming the dried portion into a film; edible; enrobing and/or encapsulating oral dosage forms |
| 03/18/2004 | US20040052838 Erythropoietin liposomal dispersion |
| 03/18/2004 | US20040052832 Acid-labile active ingredient is present in the individual active ingredient units in a matrix composed of a mixture of solid praffin, and one or more substances form fatty alcohol, fatty ester and triglyceride |
| 03/18/2004 | US20040052814 Fusion proteins for targeted delivery of antimicrobial peptides |
| 03/18/2004 | US20040052793 Antitumor agents |
| 03/18/2004 | US20040052785 Synergistic mixtures; antitumor agents |
| 03/18/2004 | US20040052784 Biotin derivatives |
| 03/18/2004 | US20040052761 Sustaine release; drug delivery; injections |
| 03/18/2004 | US20040052754 Complexes of phosphate derivatives |
| 03/18/2004 | US20040052739 Sunscreen agents; radiation resistance |
| 03/18/2004 | US20040052735 Mixture of oleoresin and spilanthol; food, drugs, cosmetics |
| 03/18/2004 | US20040052729 Immobilization carbohydrates; calibration; diagnosis; antiinflammatory agents, bactericides |
| 03/18/2004 | US20040050964 Dispensing device |
| 03/18/2004 | US20040050335 Animal feed supplement containing d-pantothenic acid and/or its salts, improved method for the production thereof, and its use |
| 03/18/2004 | DE10239238A1 Flüssigkonzentrat zur Konservierung von kosmetischen und pharmazeutischen Produkten Liquid concentrate for the preservation of cosmetic and pharmaceutical products |
| 03/18/2004 | CA2818071A1 Modified cyclodextrin ring compounds having exactly two hydroxyl moieties substituted with an amino acid for therapeutics delivery |
| 03/18/2004 | CA2707068A1 Clear ophthalmic solution comprising latanoprost as active ingredient |
| 03/18/2004 | CA2707067A1 Clear ophthalmic solution comprising latanoprost as active ingredient |
| 03/18/2004 | CA2536795A1 Modified therapeutic agents |
| 03/18/2004 | CA2497960A1 Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin |
| 03/18/2004 | CA2497792A1 Cyclodextrin-based polymers for therapeutics delivery |
| 03/18/2004 | CA2497788A1 Use of histamine h4 receptor modulators for the treatment of allergy and asthma |
| 03/18/2004 | CA2497777A1 Modified asialo-interferons and uses thereof |
| 03/18/2004 | CA2497696A1 Increasing the absorption of substances via the skin and mucous membranes |
| 03/18/2004 | CA2497548A1 Preparation of m(co)3-complexes by solid phase techniques via metal assisted cleavage from the solid support |
| 03/18/2004 | CA2497335A1 Formulation for funnelling nucleic acids into eukaryotic cells |
| 03/18/2004 | CA2497176A1 Taste masked dosage forms and processes for their preparation |
| 03/18/2004 | CA2495899A1 Solid nano pharmaceutical formulation and preparation method thereof |
| 03/18/2004 | CA2494135A1 Branched alcohol-based personal care compositions |
| 03/18/2004 | CA2493974A1 Pharmaceutical dosage form comprising a sulfite compound |
| 03/18/2004 | CA2493723A1 Methods of treatment of male erectile dysfunction |
| 03/17/2004 | EP1398377A1 Growth differentation Factor-7 |
| 03/17/2004 | EP1398369A1 Bifidobacteria and preparations containing them |
| 03/17/2004 | EP1398346A1 Molded object having high pullulan content, process for producing the same, and use thereof |
| 03/17/2004 | EP1398328A1 Hydroxyalkyl starch derivatives |
| 03/17/2004 | EP1398327A1 Method of producing hydroxyalkyl starch derivatives |
| 03/17/2004 | EP1398322A1 HASylated polypeptides, especially HASylated erythropoietin |
| 03/17/2004 | EP1398040A1 Medicinal composition |
| 03/17/2004 | EP1398038A1 Botulinum toxin pharmaceutical compositions |
| 03/17/2004 | EP1398037A2 Pharmaceutical formulations comprising a water-insoluble complex for sustained drug delivery |
| 03/17/2004 | EP1398025A1 Fine inorganic particles having drug included therein, method for preparation thereof and pharmaceutical preparation comprising fine inorganic particles having drug included therein |
| 03/17/2004 | EP1397489A2 Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof |
| 03/17/2004 | EP1397429A1 Composite particles, derived conjugates, preparation method thereof and applications of same |
| 03/17/2004 | EP1397387A1 Antibodies specific for cd44v6 |
| 03/17/2004 | EP1397386A2 Chimeric proteins for cell targeting and apoptosis induction and methods of using the same |
| 03/17/2004 | EP1397375A1 Alkyl- and/or alkenyloligoglycoside preparations having reduced magnesium salt concentrations |
| 03/17/2004 | EP1397339A1 (ethylene)-(propylene)-triaminepentaacetic acid derivatives, process for their production, and their use for the production of pharmaceutical agents |
| 03/17/2004 | EP1397162A2 Water-soluble antibiotic comprising an amino sugar, in the form of a polysaccharide conjugate |
| 03/17/2004 | EP1397161A2 Compounds comprising an analgesic molecule linked to a vector that can vectorise said molecule through the hematoencephalic barrier and pharmaceutical compositions containing same |
| 03/17/2004 | EP1397160A1 Pharmaceutical composition including ace/nep inhibitors and bioavailability enhancers |
| 03/17/2004 | EP1397159A2 Stable liquid formulations of antibodies |
| 03/17/2004 | EP1397158A2 USE OF IgM ANTIBODIES AGAINST dsDNA IN SYSTEMIC LUPUS ERYTHEMATOSUS WITH NEPHRITIS |
| 03/17/2004 | EP1397156A2 Oral administration of parathyroid hormone and calcitonin |
| 03/17/2004 | EP1397155A1 Sustained release formulation |
| 03/17/2004 | EP1397133A1 Rapid onset formulation |
| 03/17/2004 | EP1397132A1 Pirenzepine ophthalmic gel |
| 03/17/2004 | EP1397127A1 Solid pharmaceutucal formulations comprising modafinil |
| 03/17/2004 | EP1397095A1 Abuse resistant opioid containing transdermal systems |
| 03/17/2004 | EP1397053A1 Oral composition comprising an extract from the bark of albizzia myriophylla |
| 03/17/2004 | EP1397044A1 Prebiotic and probiotic compositions and methods for their use in gut-based therapies |
| 03/17/2004 | EP1292316A4 Hemostatic compositions of polyacids and polyalkylene oxides and methods for their use |
| 03/17/2004 | EP1259112A4 Nutritional intervention composition for enhancing and extending satiety |
| 03/17/2004 | EP1244434B1 Use of chemotherapeutic agents |
| 03/17/2004 | EP1202719A4 Anesthetic composition for intravenous injection comprising propofol |
| 03/17/2004 | EP1003558B1 Lipid-polyamide conjugates and compositions for nucleic acid delivery |
| 03/17/2004 | EP0986373B1 Drug targeting system, method of its preparation and its use |
| 03/17/2004 | EP0973546B1 Stabilized human papillomavirus formulations |
| 03/17/2004 | EP0970107B1 Cyclosporine derivatives and uses thereof |
| 03/17/2004 | EP0958380A4 Macromolecule-lipid complexes and methods for making and using |
| 03/17/2004 | EP0910346B1 Marking rapidly disintegrating dosage forms |
| 03/17/2004 | EP0806955B1 Enrofloxacine injection or infusion solutions |
| 03/17/2004 | EP0731807B1 N-2 substituted purines |
| 03/17/2004 | EP0655917B1 Crystalline amifostine compositions and methods for the preparation and use of same |
| 03/17/2004 | CN1482921A Compositions of estrogen-cyclodextrin complexes |
| 03/17/2004 | CN1482916A Vaccine composite containing invert growth factor a |
| 03/17/2004 | CN1482910A Famotidine injections |
| 03/17/2004 | CN1482909A Thermoformable solid pharmaceutical composition for controlled release of perindopril |
| 03/17/2004 | CN1482901A Solid themoformable pharmaceutical composition for the controlled release of ivabradine |
| 03/17/2004 | CN1482248A Amphoteric protein paster |
| 03/17/2004 | CN1481902A Preparation method for granula made of ª‡-alcoholic acid resin ,and its use |
| 03/17/2004 | CN1481901A Hla matching donor-originating activated lymphocytes |
| 03/17/2004 | CN1481896A Interferon formulation of skin-infiltrating type |
| 03/17/2004 | CN1481894A Drug composition, its preparation method and use |
| 03/17/2004 | CN1481884A Skin-infiltrating film of Chinese traditional medicine for curing paralysis resulting from central nerve trauma and its preparation method |